Global Tyrosine Kinase JAK Inhibitors Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
Page: 114
Published Date: 02 Jan 2024
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Tyrosine Kinase JAK Inhibitors market size was valued at USD 31360 million in 2023 and is forecast to a readjusted size of USD 497670 million by 2030 with a CAGR of 48.4% during review period.
Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.
These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis. There is interest in their use for various skin conditions. JAK3 inhibitors are attractive as a possible treatment of various autoimmune diseases since its functions is mainly restricted to lymphocytes. Development for a selective JAK3 inhibitors are ongoing.
In the report, we only count drugs for human beings. And the 1 unit is 1 tablet.
The classification of Tyrosine Kinase JAK Inhibitors includes Tofacitinib, Ruxolitinib and Baricitinib, and the proportion of Ruxolitinib is about 56%.
Tyrosine Kinase JAK Inhibitors is widely used in Rheumatoid Arthritis (RA), Polycythemia Vera (PCV) and Myelofibrosis (MF). The most proportion of Tyrosine Kinase JAK Inhibitors is for Rheumatoid Arthritis (RA), and the proportion is about 37%.
North America is the largest consumption place, with a consumption market share nearly 56%. Following North America, Europe is the second largest consumption place with the consumption market share of 39%.
Market competition is intense. Pfizer, Incyte, Novartis, Eli Lilly are the leaders of the industry. Pfizer is the leader of this industry with about 42% market sharers.
The Global Info Research report includes an overview of the development of the Tyrosine Kinase JAK Inhibitors industry chain, the market status of Rheumatoid Arthritis (RA) (Tofacitinib, Ruxolitinib), Polycythemia Vera (PCV) (Tofacitinib, Ruxolitinib), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Tyrosine Kinase JAK Inhibitors.
Regionally, the report analyzes the Tyrosine Kinase JAK Inhibitors markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Tyrosine Kinase JAK Inhibitors market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Tyrosine Kinase JAK Inhibitors market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Tyrosine Kinase JAK Inhibitors industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Tofacitinib, Ruxolitinib).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Tyrosine Kinase JAK Inhibitors market.
Regional Analysis: The report involves examining the Tyrosine Kinase JAK Inhibitors market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Tyrosine Kinase JAK Inhibitors market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Tyrosine Kinase JAK Inhibitors:
Company Analysis: Report covers individual Tyrosine Kinase JAK Inhibitors manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Tyrosine Kinase JAK Inhibitors This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Rheumatoid Arthritis (RA), Polycythemia Vera (PCV)).
Technology Analysis: Report covers specific technologies relevant to Tyrosine Kinase JAK Inhibitors. It assesses the current state, advancements, and potential future developments in Tyrosine Kinase JAK Inhibitors areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Tyrosine Kinase JAK Inhibitors market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Tyrosine Kinase JAK Inhibitors market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Tofacitinib
Ruxolitinib
Baricitinib
Market segment by Application
Rheumatoid Arthritis (RA)
Polycythemia Vera (PCV)
Myelofibrosis (MF)
Others
Major players covered
Pfizer
Incyte
Novartis
Eli Lilly
Gilead
Sanofi
Galapagos
AbbVie
Vertex
Teva
Astellas Pharma
Celgene
CTI BioPharma
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Tyrosine Kinase JAK Inhibitors product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tyrosine Kinase JAK Inhibitors, with price, sales, revenue and global market share of Tyrosine Kinase JAK Inhibitors from 2019 to 2024.
Chapter 3, the Tyrosine Kinase JAK Inhibitors competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tyrosine Kinase JAK Inhibitors breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Tyrosine Kinase JAK Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tyrosine Kinase JAK Inhibitors.
Chapter 14 and 15, to describe Tyrosine Kinase JAK Inhibitors sales channel, distributors, customers, research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Tyrosine Kinase JAK Inhibitors
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Tofacitinib
1.3.3 Ruxolitinib
1.3.4 Baricitinib
1.4 Market Analysis by Application
1.4.1 Overview: Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Rheumatoid Arthritis (RA)
1.4.3 Polycythemia Vera (PCV)
1.4.4 Myelofibrosis (MF)
1.4.5 Others
1.5 Global Tyrosine Kinase JAK Inhibitors Market Size & Forecast
1.5.1 Global Tyrosine Kinase JAK Inhibitors Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Tyrosine Kinase JAK Inhibitors Sales Quantity (2019-2030)
1.5.3 Global Tyrosine Kinase JAK Inhibitors Average Price (2019-2030)
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Tyrosine Kinase JAK Inhibitors Product and Services
2.1.4 Pfizer Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Pfizer Recent Developments/Updates
2.2 Incyte
2.2.1 Incyte Details
2.2.2 Incyte Major Business
2.2.3 Incyte Tyrosine Kinase JAK Inhibitors Product and Services
2.2.4 Incyte Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Incyte Recent Developments/Updates
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Tyrosine Kinase JAK Inhibitors Product and Services
2.3.4 Novartis Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Novartis Recent Developments/Updates
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business
2.4.3 Eli Lilly Tyrosine Kinase JAK Inhibitors Product and Services
2.4.4 Eli Lilly Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Eli Lilly Recent Developments/Updates
2.5 Gilead
2.5.1 Gilead Details
2.5.2 Gilead Major Business
2.5.3 Gilead Tyrosine Kinase JAK Inhibitors Product and Services
2.5.4 Gilead Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Gilead Recent Developments/Updates
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Tyrosine Kinase JAK Inhibitors Product and Services
2.6.4 Sanofi Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Sanofi Recent Developments/Updates
2.7 Galapagos
2.7.1 Galapagos Details
2.7.2 Galapagos Major Business
2.7.3 Galapagos Tyrosine Kinase JAK Inhibitors Product and Services
2.7.4 Galapagos Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Galapagos Recent Developments/Updates
2.8 AbbVie
2.8.1 AbbVie Details
2.8.2 AbbVie Major Business
2.8.3 AbbVie Tyrosine Kinase JAK Inhibitors Product and Services
2.8.4 AbbVie Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 AbbVie Recent Developments/Updates
2.9 Vertex
2.9.1 Vertex Details
2.9.2 Vertex Major Business
2.9.3 Vertex Tyrosine Kinase JAK Inhibitors Product and Services
2.9.4 Vertex Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Vertex Recent Developments/Updates
2.10 Teva
2.10.1 Teva Details
2.10.2 Teva Major Business
2.10.3 Teva Tyrosine Kinase JAK Inhibitors Product and Services
2.10.4 Teva Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Teva Recent Developments/Updates
2.11 Astellas Pharma
2.11.1 Astellas Pharma Details
2.11.2 Astellas Pharma Major Business
2.11.3 Astellas Pharma Tyrosine Kinase JAK Inhibitors Product and Services
2.11.4 Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Astellas Pharma Recent Developments/Updates
2.12 Celgene
2.12.1 Celgene Details
2.12.2 Celgene Major Business
2.12.3 Celgene Tyrosine Kinase JAK Inhibitors Product and Services
2.12.4 Celgene Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Celgene Recent Developments/Updates
2.13 CTI BioPharma
2.13.1 CTI BioPharma Details
2.13.2 CTI BioPharma Major Business
2.13.3 CTI BioPharma Tyrosine Kinase JAK Inhibitors Product and Services
2.13.4 CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 CTI BioPharma Recent Developments/Updates
3.1 Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Manufacturer (2019-2024)
3.2 Global Tyrosine Kinase JAK Inhibitors Revenue by Manufacturer (2019-2024)
3.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Tyrosine Kinase JAK Inhibitors by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Tyrosine Kinase JAK Inhibitors Manufacturer Market Share in 2023
3.4.2 Top 6 Tyrosine Kinase JAK Inhibitors Manufacturer Market Share in 2023
3.5 Tyrosine Kinase JAK Inhibitors Market: Overall Company Footprint Analysis
3.5.1 Tyrosine Kinase JAK Inhibitors Market: Region Footprint
3.5.2 Tyrosine Kinase JAK Inhibitors Market: Company Product Type Footprint
3.5.3 Tyrosine Kinase JAK Inhibitors Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Tyrosine Kinase JAK Inhibitors Market Size by Region
4.1.1 Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2019-2030)
4.1.2 Global Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2019-2030)
4.1.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Region (2019-2030)
4.2 North America Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030)
4.3 Europe Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030)
4.4 Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030)
4.5 South America Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030)
4.6 Middle East and Africa Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030)
5.1 Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2030)
5.2 Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type (2019-2030)
5.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Type (2019-2030)
6.1 Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2030)
6.2 Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application (2019-2030)
6.3 Global Tyrosine Kinase JAK Inhibitors Average Price by Application (2019-2030)
7.1 North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2030)
7.2 North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2030)
7.3 North America Tyrosine Kinase JAK Inhibitors Market Size by Country
7.3.1 North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2019-2030)
7.3.2 North America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8.1 Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2030)
8.2 Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2030)
8.3 Europe Tyrosine Kinase JAK Inhibitors Market Size by Country
8.3.1 Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2019-2030)
8.3.2 Europe Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9.1 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Tyrosine Kinase JAK Inhibitors Market Size by Region
9.3.1 Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10.1 South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2030)
10.2 South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2030)
10.3 South America Tyrosine Kinase JAK Inhibitors Market Size by Country
10.3.1 South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2019-2030)
10.3.2 South America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11.1 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Tyrosine Kinase JAK Inhibitors Market Size by Country
11.3.1 Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12.1 Tyrosine Kinase JAK Inhibitors Market Drivers
12.2 Tyrosine Kinase JAK Inhibitors Market Restraints
12.3 Tyrosine Kinase JAK Inhibitors Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13.1 Raw Material of Tyrosine Kinase JAK Inhibitors and Key Manufacturers
13.2 Manufacturing Costs Percentage of Tyrosine Kinase JAK Inhibitors
13.3 Tyrosine Kinase JAK Inhibitors Production Process
13.4 Tyrosine Kinase JAK Inhibitors Industrial Chain
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Tyrosine Kinase JAK Inhibitors Typical Distributors
14.3 Tyrosine Kinase JAK Inhibitors Typical Customers
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Major Business
Table 5. Pfizer Tyrosine Kinase JAK Inhibitors Product and Services
Table 6. Pfizer Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Pfizer Recent Developments/Updates
Table 8. Incyte Basic Information, Manufacturing Base and Competitors
Table 9. Incyte Major Business
Table 10. Incyte Tyrosine Kinase JAK Inhibitors Product and Services
Table 11. Incyte Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Incyte Recent Developments/Updates
Table 13. Novartis Basic Information, Manufacturing Base and Competitors
Table 14. Novartis Major Business
Table 15. Novartis Tyrosine Kinase JAK Inhibitors Product and Services
Table 16. Novartis Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Novartis Recent Developments/Updates
Table 18. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 19. Eli Lilly Major Business
Table 20. Eli Lilly Tyrosine Kinase JAK Inhibitors Product and Services
Table 21. Eli Lilly Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Eli Lilly Recent Developments/Updates
Table 23. Gilead Basic Information, Manufacturing Base and Competitors
Table 24. Gilead Major Business
Table 25. Gilead Tyrosine Kinase JAK Inhibitors Product and Services
Table 26. Gilead Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Gilead Recent Developments/Updates
Table 28. Sanofi Basic Information, Manufacturing Base and Competitors
Table 29. Sanofi Major Business
Table 30. Sanofi Tyrosine Kinase JAK Inhibitors Product and Services
Table 31. Sanofi Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Sanofi Recent Developments/Updates
Table 33. Galapagos Basic Information, Manufacturing Base and Competitors
Table 34. Galapagos Major Business
Table 35. Galapagos Tyrosine Kinase JAK Inhibitors Product and Services
Table 36. Galapagos Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Galapagos Recent Developments/Updates
Table 38. AbbVie Basic Information, Manufacturing Base and Competitors
Table 39. AbbVie Major Business
Table 40. AbbVie Tyrosine Kinase JAK Inhibitors Product and Services
Table 41. AbbVie Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. AbbVie Recent Developments/Updates
Table 43. Vertex Basic Information, Manufacturing Base and Competitors
Table 44. Vertex Major Business
Table 45. Vertex Tyrosine Kinase JAK Inhibitors Product and Services
Table 46. Vertex Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Vertex Recent Developments/Updates
Table 48. Teva Basic Information, Manufacturing Base and Competitors
Table 49. Teva Major Business
Table 50. Teva Tyrosine Kinase JAK Inhibitors Product and Services
Table 51. Teva Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Teva Recent Developments/Updates
Table 53. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 54. Astellas Pharma Major Business
Table 55. Astellas Pharma Tyrosine Kinase JAK Inhibitors Product and Services
Table 56. Astellas Pharma Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 57. Astellas Pharma Recent Developments/Updates
Table 58. Celgene Basic Information, Manufacturing Base and Competitors
Table 59. Celgene Major Business
Table 60. Celgene Tyrosine Kinase JAK Inhibitors Product and Services
Table 61. Celgene Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 62. Celgene Recent Developments/Updates
Table 63. CTI BioPharma Basic Information, Manufacturing Base and Competitors
Table 64. CTI BioPharma Major Business
Table 65. CTI BioPharma Tyrosine Kinase JAK Inhibitors Product and Services
Table 66. CTI BioPharma Tyrosine Kinase JAK Inhibitors Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 67. CTI BioPharma Recent Developments/Updates
Table 68. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 69. Global Tyrosine Kinase JAK Inhibitors Revenue by Manufacturer (2019-2024) & (USD Million)
Table 70. Global Tyrosine Kinase JAK Inhibitors Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 71. Market Position of Manufacturers in Tyrosine Kinase JAK Inhibitors, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 72. Head Office and Tyrosine Kinase JAK Inhibitors Production Site of Key Manufacturer
Table 73. Tyrosine Kinase JAK Inhibitors Market: Company Product Type Footprint
Table 74. Tyrosine Kinase JAK Inhibitors Market: Company Product Application Footprint
Table 75. Tyrosine Kinase JAK Inhibitors New Market Entrants and Barriers to Market Entry
Table 76. Tyrosine Kinase JAK Inhibitors Mergers, Acquisition, Agreements, and Collaborations
Table 77. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2019-2024) & (K Units)
Table 78. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2025-2030) & (K Units)
Table 79. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2019-2024) & (USD Million)
Table 80. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2025-2030) & (USD Million)
Table 81. Global Tyrosine Kinase JAK Inhibitors Average Price by Region (2019-2024) & (USD/Unit)
Table 82. Global Tyrosine Kinase JAK Inhibitors Average Price by Region (2025-2030) & (USD/Unit)
Table 83. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2024) & (K Units)
Table 84. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2025-2030) & (K Units)
Table 85. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type (2019-2024) & (USD Million)
Table 86. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type (2025-2030) & (USD Million)
Table 87. Global Tyrosine Kinase JAK Inhibitors Average Price by Type (2019-2024) & (USD/Unit)
Table 88. Global Tyrosine Kinase JAK Inhibitors Average Price by Type (2025-2030) & (USD/Unit)
Table 89. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2024) & (K Units)
Table 90. Global Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2025-2030) & (K Units)
Table 91. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application (2019-2024) & (USD Million)
Table 92. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application (2025-2030) & (USD Million)
Table 93. Global Tyrosine Kinase JAK Inhibitors Average Price by Application (2019-2024) & (USD/Unit)
Table 94. Global Tyrosine Kinase JAK Inhibitors Average Price by Application (2025-2030) & (USD/Unit)
Table 95. North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2024) & (K Units)
Table 96. North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2025-2030) & (K Units)
Table 97. North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2024) & (K Units)
Table 98. North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2025-2030) & (K Units)
Table 99. North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2019-2024) & (K Units)
Table 100. North America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2025-2030) & (K Units)
Table 101. North America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2019-2024) & (USD Million)
Table 102. North America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2025-2030) & (USD Million)
Table 103. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2024) & (K Units)
Table 104. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2025-2030) & (K Units)
Table 105. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2024) & (K Units)
Table 106. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2025-2030) & (K Units)
Table 107. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2019-2024) & (K Units)
Table 108. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2025-2030) & (K Units)
Table 109. Europe Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2019-2024) & (USD Million)
Table 110. Europe Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2025-2030) & (USD Million)
Table 111. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2024) & (K Units)
Table 112. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2025-2030) & (K Units)
Table 113. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2024) & (K Units)
Table 114. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2025-2030) & (K Units)
Table 115. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2019-2024) & (K Units)
Table 116. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2025-2030) & (K Units)
Table 117. Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2019-2024) & (USD Million)
Table 118. Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2025-2030) & (USD Million)
Table 119. South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2024) & (K Units)
Table 120. South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2025-2030) & (K Units)
Table 121. South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2024) & (K Units)
Table 122. South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2025-2030) & (K Units)
Table 123. South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2019-2024) & (K Units)
Table 124. South America Tyrosine Kinase JAK Inhibitors Sales Quantity by Country (2025-2030) & (K Units)
Table 125. South America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2019-2024) & (USD Million)
Table 126. South America Tyrosine Kinase JAK Inhibitors Consumption Value by Country (2025-2030) & (USD Million)
Table 127. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2019-2024) & (K Units)
Table 128. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Type (2025-2030) & (K Units)
Table 129. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2019-2024) & (K Units)
Table 130. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Application (2025-2030) & (K Units)
Table 131. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2019-2024) & (K Units)
Table 132. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity by Region (2025-2030) & (K Units)
Table 133. Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2019-2024) & (USD Million)
Table 134. Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Value by Region (2025-2030) & (USD Million)
Table 135. Tyrosine Kinase JAK Inhibitors Raw Material
Table 136. Key Manufacturers of Tyrosine Kinase JAK Inhibitors Raw Materials
Table 137. Tyrosine Kinase JAK Inhibitors Typical Distributors
Table 138. Tyrosine Kinase JAK Inhibitors Typical Customers
List of Figures
Figure 1. Tyrosine Kinase JAK Inhibitors Picture
Figure 2. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Type in 2023
Figure 4. Tofacitinib Examples
Figure 5. Ruxolitinib Examples
Figure 6. Baricitinib Examples
Figure 7. Global Tyrosine Kinase JAK Inhibitors Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Application in 2023
Figure 9. Rheumatoid Arthritis (RA) Examples
Figure 10. Polycythemia Vera (PCV) Examples
Figure 11. Myelofibrosis (MF) Examples
Figure 12. Others Examples
Figure 13. Global Tyrosine Kinase JAK Inhibitors Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global Tyrosine Kinase JAK Inhibitors Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Tyrosine Kinase JAK Inhibitors Sales Quantity (2019-2030) & (K Units)
Figure 16. Global Tyrosine Kinase JAK Inhibitors Average Price (2019-2030) & (USD/Unit)
Figure 17. Global Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Manufacturer in 2023
Figure 18. Global Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Manufacturer in 2023
Figure 19. Producer Shipments of Tyrosine Kinase JAK Inhibitors by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 20. Top 3 Tyrosine Kinase JAK Inhibitors Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Top 6 Tyrosine Kinase JAK Inhibitors Manufacturer (Consumption Value) Market Share in 2023
Figure 22. Global Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Region (2019-2030)
Figure 23. Global Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Region (2019-2030)
Figure 24. North America Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030) & (USD Million)
Figure 25. Europe Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030) & (USD Million)
Figure 26. Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030) & (USD Million)
Figure 27. South America Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030) & (USD Million)
Figure 28. Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Value (2019-2030) & (USD Million)
Figure 29. Global Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Type (2019-2030)
Figure 30. Global Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Type (2019-2030)
Figure 31. Global Tyrosine Kinase JAK Inhibitors Average Price by Type (2019-2030) & (USD/Unit)
Figure 32. Global Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Application (2019-2030)
Figure 33. Global Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Application (2019-2030)
Figure 34. Global Tyrosine Kinase JAK Inhibitors Average Price by Application (2019-2030) & (USD/Unit)
Figure 35. North America Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Type (2019-2030)
Figure 36. North America Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Application (2019-2030)
Figure 37. North America Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Country (2019-2030)
Figure 38. North America Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Country (2019-2030)
Figure 39. United States Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Canada Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Mexico Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 42. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Type (2019-2030)
Figure 43. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Application (2019-2030)
Figure 44. Europe Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Country (2019-2030)
Figure 45. Europe Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Country (2019-2030)
Figure 46. Germany Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. France Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. United Kingdom Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Russia Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Italy Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Type (2019-2030)
Figure 52. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Application (2019-2030)
Figure 53. Asia-Pacific Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Region (2019-2030)
Figure 54. Asia-Pacific Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Region (2019-2030)
Figure 55. China Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Japan Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Korea Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. India Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Southeast Asia Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. Australia Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. South America Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Type (2019-2030)
Figure 62. South America Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Application (2019-2030)
Figure 63. South America Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Country (2019-2030)
Figure 64. South America Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Country (2019-2030)
Figure 65. Brazil Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Argentina Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 67. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Type (2019-2030)
Figure 68. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Application (2019-2030)
Figure 69. Middle East & Africa Tyrosine Kinase JAK Inhibitors Sales Quantity Market Share by Region (2019-2030)
Figure 70. Middle East & Africa Tyrosine Kinase JAK Inhibitors Consumption Value Market Share by Region (2019-2030)
Figure 71. Turkey Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Egypt Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. Saudi Arabia Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. South Africa Tyrosine Kinase JAK Inhibitors Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Tyrosine Kinase JAK Inhibitors Market Drivers
Figure 76. Tyrosine Kinase JAK Inhibitors Market Restraints
Figure 77. Tyrosine Kinase JAK Inhibitors Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Tyrosine Kinase JAK Inhibitors in 2023
Figure 80. Manufacturing Process Analysis of Tyrosine Kinase JAK Inhibitors
Figure 81. Tyrosine Kinase JAK Inhibitors Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Pfizer Incyte Novartis Eli Lilly Gilead Sanofi Galapagos AbbVie Vertex Teva Astellas Pharma Celgene CTI BioPharma
18 Mar 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
